Quarterly report [Sections 13 or 15(d)]

Condensed Consolidated Statements of Cash Flows (Unaudited)

v3.26.3
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Cash Flows From Operating Activities    
Net (loss) income $ (731,000) $ 1,918,000
Adjustments to reconcile net income to net cash provided by operating activities:    
Depreciation and amortization 386,000 307,000
Amortization of deferred financing fees 42,000
Stock-based compensation 4,001,000 31,000
Deferred taxes (543,000)
Asset impairment - lab supplies 198,000
Lab supplies write-off 217,000
Loss on sale of asset 104,000
Change in fair value of note payable 87,000
Amortization on operating lease right of use asset 329,000 293,000
Other changes in operating assets and liabilities:    
Accounts receivable (1,950,000) 2,578,000
Other current assets (869,000) (213,000)
Accounts payable 481,000 (417,000)
Accrued salary and bonus 507,000 (777,000)
Other accrued expenses (508,000) (385,000)
Operating lease liabilities (400,000) (283,000)
Other long-term liabilities 327,000 314,000
Net cash provided by operating activities 1,351,000 3,693,000
Cash Flows From Investing Activities    
Purchase of property and equipment (574,000) (318,000)
Sale of property and equipment 7,000
Net cash used in investing activities (567,000) (318,000)
Cash Flows From Financing Activities    
Payments made on note payable (3,400,000)
Payment of deferred offering costs (360,000)
Series C conversion costs (13,000)
Net cash used in financing activities (360,000) (3,413,000)
Net increase (decrease) in cash and cash equivalents 424,000 (38,000)
Cash and cash equivalents – beginning 2,505,000 1,461,000
Cash and cash equivalents – ending $ 2,929,000 $ 1,423,000